Pricing Log in Create free account

LENZ Therapeutics, Inc. (LENZ) vs Outlook Therapeutics, Inc. (OTLK)

LENZ Therapeutics, Inc. and Outlook Therapeutics, Inc. are both Biotechnology companies. Outlook Therapeutics, Inc. is the larger, with a market value of $106.9M against $94.6M — 1.1× the size. Outlook Therapeutics, Inc. has the higher net margin (5,253.4% vs −1,135.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Outlook Therapeutics, Inc. leads on 10 and LENZ Therapeutics, Inc. on 3.

Valuation

Metric LENZ OTLK Biotechnology median
P/E n/m n/m 10.26
P/S 7.73 n/m 9.18
P/B 0.50 n/m 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 0.67 n/m 0.65
EV/Sales (8.06) (67.28) 8.98
Earnings yield (147.55%) (195.93%) (34.89%)
Free cash flow yield (133.70%) (94.06%) (24.52%)

Profitability

Metric LENZ OTLK Biotechnology median
Gross margin 85.35% 195.62% 65.16%
Operating margin (1,211.17%) 4,781.76% 0.00%
Net margin (1,134.97%) 5,253.40% 0.00%
Free cash flow margin (1,033.28%) 4,826.38% 0.00%
Return on equity (72.69%) 256.92% (50.12%)
Return on assets (66.72%) (251.66%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LENZ OTLK Biotechnology median
Revenue growth (TTM) — (113.55%) 6.26%
EPS growth (last fiscal year) (21.79%) 55.81% 29.88%
Revenue growth, 5-year CAGR — (22.99%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LENZ OTLK Biotechnology median
Debt to equity 0.00 (1.75) 0.00
Current ratio 11.66 0.81 4.89
Net debt to EBITDA 3.22 (0.33) 1.01

Dividend

Metric LENZ OTLK Biotechnology median
Dividend yield 0.00% — 0.41%
Payout ratio — — —

Size

Metric LENZ OTLK Biotechnology median
Market cap 94.58m 106.90m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack